Can Cutting-Edge Insulin Hold Off Cheap Generics?
The Motley Fool's health-care show Market Checkup focuses this week on diabetes, one of America's growing health-care concerns. There are two versions of this chronic disease, the more prevalent being type 2 diabetes, which makes up about 95% of all cases. Because of the overwhelming patient population, type 2 diabetes receives the majority of attention from Big Pharma companies.
Diabetes is no small problem. In 2010, one in 10 adults had diabetes, and more troubling, more than one in four senior citizens suffered from it. Diabetes is the seventh leading cause of death, and there are 2 million new cases in America every year, leading analysts to project spending on diabetes to approach $60 billion in just five years. And this isn't just an American problem: 370 million suffer from diabetes around the world.
In this video, health-care analysts David Williamson and Max Macaluso discuss the cutting edge of insulin treatments, including a new long-acting insulin by Sanofi. The pharma currently dominates the insulin market, but generic competition is on the way. Watch as David and Max discuss whether Sanofi's newest insulin in development, U300, can use better performance to hold on to the company's market share.
Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health-care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may impact your taxes, health insurance, and investments. Click here for your free copy today.
The article Can Cutting-Edge Insulin Hold Off Cheap Generics? originally appeared on Fool.com.
David Williamson owns shares of Eli Lilly. Follow David on Twitter: @MotleyDavid.Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
